Glaxosmithkline Pharmaceuticals Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/bd7ciihn1l2nxs7a74uih9i9.pdf

Key Takeaways


Top-Line Growth & Demand Environment

Akshikar: "I think it's safe to say that the worst is behind us. I think we learned, we've used those learnings from the unfortunate incident that we had at one CMO to stress-test the entire supply chain."

Innovation Portfolio & Specialty Pipeline

Akshikar: "The concept of functional cure is almost non-existent in chronic hepatitis B. Now when you look at a country like ours apart from some other countries in Asia, the burden of disease is the highest here. I mean we have more than 4 crore patients who have chronic hepatitis B."

Vaccines

Akshikar: "We're selling upwards of 45,000, 50,000 doses now on a quarterly basis. And that goes back to what we had said a couple of years back. Given India's demographic, given the large number of 50 plus adults and underlying -- with underlying comorbidities especially cardiovascular, comorbidities including areas like diabetes mellitus. I think we see an incredible future in the coming months only to build on this trend."

General Medicines & Operating Model

Akshikar: "I think we're one of the few markets where we still have double-digit growth for our general medicines business. As we all know, our products are still relevant, they still create tremendous value for patients at large and they are not only brands here, as I always say, they are trust marks in terms of the value that they bring in."

Margins, Investment & Profitability

Biswas: "We expect our S&A ratios to normalize to historical as you move through the year and EBITDA margins to be roughly what we were at last year in 34% kind of range."

Strategic Vision & Long-Term Bets

Akshikar: "I think EBITDA is an outcome, our focus is to deliver that top-line growth. I think that's the single-minded focus that we have; the double-digit growth that I've talked about for the last few years is the single-minded objective we have."

Guidance & Commitments

CommitmentSpecificsTimeline
Blenrep launchAntibody drug conjugate for second-line refractory relapsed multiple myelomaQ2 FY27, or Q3 at the latest (next 2–3 months)
Bepirovirsen launchFunctional cure for chronic hepatitis B, subject to trial outcomesStill 3–4 quarters away at minimum
Full-year EBITDA marginRoughly at last year's ~34% rangeFY27
S&A ratio normalizationInvestment ratios to moderate and return to historical trendsThrough the remaining quarters of FY27
Vaccine phasing correctionAvailability issues for a couple of vaccines to be resolvedQ2 FY27
Jemperli additional indicationsNews on rectal cancer trialsNext 2–3 months, hopefully within FY27 or Q1 next year
Top-line growth objectiveSustain double-digit momentum; no formal forward guidanceComing quarters

Key Metrics

MetricQ1 FY27
Revenue₹924 cr, +15% YoY; +4%–5% from favorable base effect, sustainable growth at 9%–10%
EBITDA growth+17% YoY, two percentage points ahead of sales growth
EBITDA marginImproved 50 bps YoY; gross margin up ~150 bps, spend-to-sales ratio up ~1 ppt
PAT₹253 cr, +24% YoY; +17% excluding one-off dividend from Biddle Sawyer subsidiary
PAT margin27.6%, expansion of 200 bps YoY
EPS₹14.95 for the quarter
Innovation portfolio share of revenue7% of total revenues, vs ~4% in Q1 FY26; contributed about 4 ppt of headline growth
Gross marginImproved ~150 bps YoY, helped by pricing and product mix; partly offset by rupee depreciation on imports
Volume growth~3%–3.5% blended across entire business
Price growth~6% for the quarter
Shingrix growth+65% YoY; crossed ₹100 cr on MAT basis; 45,000–50,000 doses sold in the quarter
Nucala new patient adds~100–120 patients per month, doubled from ~50–60 per month in Q1 FY26; ~600 patients on active treatment
Trelegy Ellipta monthly units10,000–12,000 units per month, holding share despite 10–12 generic launches
Oncology patients treated~260–270 patients in Q1; Jemperli + Zejula combined ~250–300 patients per quarter
MR productivity₹15 lakhs–₹16 lakhs per rep blended average; improved 5%–6% QoQ
Opex growth+36% YoY, driven by deliberate front-loading of ~3,800 HCP events and product-focused marketing investments
EBITDA margin outlook~34% for FY27, in line with last year (per management commentary)